Scalper1 News
Generic-drug maker and IBD 50 stock Akorn’s fourth-quarter earnings and 2015 guidance beat Wall Street’s estimates, sending the stock to a new high. Akorn’s earnings excluding one-time items jumped 257% from a year earlier to 50 cents a share in Q4, topping analysts’ consensus by 5 cents, according to Thomson Reuters. Sales climbed 168% to $227.8 million, about $10 million above the Street’s average prediction. For the year, earnings Scalper1 News
Scalper1 News